TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers by Kimberly J. Briggs, Kevin M. Cottrell, Matthew R. Tonini, Alice Tsai, Minjie Zhang, Douglas A. Whittington, Wenhai Zhang, Steven A. Lombardo, Satoshi Yoda, Erik W. Wilker, Samuel R. Meier, Yi Yu, Teng Teng, Alan Huang, John P. Maxwell

Subjects: Get full text

Inhibitory Effect of PRMT5/MTA Inhibitor on MTAP‐Deficient Glioma May Be Influenced by Surrounding Normal Cells by Yunjie Wang, Xiaohui Sun, Runchen Ma, Xiaofan Zhang, Shengmin Ji, Zhaofeng Liu, Gangqiang Yang, Hongbo Wang, Peng Zhang, Jianzhao Zhang, Jingwei Tian

Subjects: Get full text

Loss of MTAP expression is strongly linked to homozygous 9p21 deletion, unfavorable tumor phenotype, and noninflamed microenvironment in urothelial bladder cancer by Natalia Gorbokon, Niklas Wößner, Viktoria Ahlburg, Henning Plage, Sebastian Hofbauer, Kira Furlano, Sarah Weinberger, Paul Giacomo Bruch, Simon Schallenberg, Florian Roßner, Sefer Elezkurtaj, Maximilian Lennartz, Niclas C Blessin, Andreas H Marx, Henrik Samtleben, Margit Fisch, Michael Rink, Marcin Slojewski, Krystian Kaczmarek, Thorsten Ecke, Tobias Klatte, Stefan Koch, Nico Adamini, Sarah Minner, Ronald Simon, Guido Sauter, Henrik Zecha, David Horst, Thorsten Schlomm, Lukas Bubendorf, Martina Kluth

Subjects: “…MTAP…”
Get full text